Bayer ties up with S’pore research centres to discover cancer drugs
SINGAPORE – Bayer HealthCare and five research institutions in Singapore have established an Integrated Translational Oncology Network to enhance research and development collaborations in the fight against cancer.
The establishment of the network was supported and facilitated by the Singapore Economic Development Board (EDB).
Network partners will share their strategic vision and jointly develop and evaluate treatment options in collaborative projects and trials for prevalent cancers in Asia
In addition, they will organise joint activities – such as annual meetings, workshops, or lectures – and link their network and activities to other leading centres in the Asia Pacific.
Mr Kevin Lai, Director, Biomedical Sciences, EDB, said: “Singapore will continue to enhance the ecosystem through investments in new infrastructure and capabilities. The BMS Industry Partnership Office which actively facilitates collaborations with the different research and clinical institutions is an excellent example of how Singapore is making the environment even more conducive for industry to conduct translational research here.”
Mr. Thomas Steffen, Country Division Head of Bayer HealthCare Pharmaceuticals for Singapore, Malaysia and Brunei said Singapore is uniquely positioned as a research hub as it provides access to the key ethnic groups in Asia.
This affords research groups greater clinical insights to the disease biology of Asian prevalent cancers in an environment with access to the necessary research facilities and scientific infrastructure.
Source: YourHealth, AsiaOne
Category: Pharmaceuticals
